Keyence

Phase A — Understand the business

Lens 1 · Company Overview

Keyence sells the eyes, rulers, and nervous system of the automated factory — sensors, machine-vision systems, laser markers, measurement instruments, and digital microscopes — to roughly 350,000 customers across ~110 countries. It is, on the numbers, the most profitable hardware company on earth: FY2026 net sales ¥1.17 trillion (+10.4% YoY), operating income ¥595.7B (+8.4%) at a 51.0% operating margin, net income ¥445.1B (+11.7%) — the fifth consecutive record profit. Gross margin runs >80% (one source cites 83.0% ).

The business model is the moat, and it has two legs that reinforce each other:

1. Fabless manufacturing. Keyence does R&D, product planning, and final assembly/QC in-house but outsources ~90% of manufacturing to contract makers. That strips out the capital intensity that caps every other industrial's margin — capex is a rounding error, so nearly every incremental yen of gross profit drops through. This is why a sensor company earns software-like margins.

2. Consultative direct sales. No distributors. Keyence hires engineering graduates and turns them into on-site consultants who walk the customer's factory floor, find the automation bottleneck the customer hadn't articulated, and spec the solution. ~3,000 sales staff (≈30% of ~10,000 employees) each file ~12 "Needs Cards" a year → ~36,000 fresh problem-statements annually that feed the product roadmap. The salesforce is simultaneously the distribution channel and the market-research org.

Contract structure: transactional, not recurring — Keyence sells hardware (10,000+ SKUs) with a same-day/next-day delivery promise it funds by carrying ~163 days of inventory. There is no big take-or-pay backlog and no single-customer concentration disclosed; revenue is spread across automotive, semiconductor, electronics, food/pharma, and general manufacturing. That breadth is a feature — no one end-market can sink it.

Reports as a single segment in statutory filings — it does not break out product-line P&L, which is itself a (deliberate) disclosure choice (see Lens 10).

Lens 2 · Supply Chain

Keyence sits in the middle of the automation value chain and has engineered itself to be the low-capital, high-margin node:

Upstream (inputs → Keyence):

• Semiconductors / image sensors / lasers / optics — CMOS sensors, laser diodes, FPGAs, MCUs sourced from the broad electronics supply base. No single named critical supplier is publicly disclosed; the fabless model means Keyence is a buyer of chips and modules, not a fab operator.
• Contract manufacturers (EMS/ODM) — ~90% of physical production is outsourced. Keyence keeps final assembly, calibration, and QC. Specific CM partners are n/a — not disclosed (a governance opacity point, Lens 10). The Takatsuki logistics hub anchors distribution.

Keyence (the value-add node): product design, firmware/algorithms (increasingly AI-based defect detection), the applications-engineering know-how embedded in the salesforce, and the just-in-time inventory buffer.

Downstream (Keyence → end customer): sold direct to factory floors — automotive OEMs and Tier-1s, semiconductor and electronics fabs, food/beverage, pharma, logistics. No distributor layer to skim margin or dilute the customer relationship.

Chokepoints / single-source dependencies: the honest read is that Keyence's supply chain is deliberately un-concentrated on the input side (commodity electronics, multiple CMs) — its scarcity is on the output side (the salesforce and the accumulated applications library). The one genuine exposure is the same one every electronics buyer carries: an acute chip/optics shortage would pinch product availability, but Keyence's pricing power and inventory buffer cushion it better than peers.

Commercial-layer note: the robotics wiki files (positioning.md, supply-chain.md, market-structure.md) are pointers in the research index but resolve to empty on disk — no compiled supply-chain map to lean on, so this lens is web-derived.

Lens 3 · Competitive Advantages (moats)

Keyence's moat is not one thing — it's the compounding interaction of four, which is precisely why it has been un-copied for 40 years:

1. The consultative salesforce (the real moat). Rivals sell products; Keyence sells solutions found on your factory floor. Switching away means giving up the engineer who knows your line. High switching costs, and a data flywheel: 36,000 Needs Cards/year → products that hit unmet needs → ~70% of new products carry a "world-first / industry-first" feature. That is a moat you cannot buy — you'd have to rebuild a 3,000-engineer culture.

2. Fabless economics as a weapon. ~50% operating margins mean Keyence can out-invest, out-price, and out-wait any competitor while still earning more. It can afford to sell a standardized premium product at a price a bespoke integrator can't match on ROI.

3. Pricing power / bargaining position. Over customers: Keyence wins because it quantifies ROI ("this sensor pays back in X months"), so it rarely competes on price. Over suppliers: as a fabless buyer of commodity electronics spread across many CMs, it holds the whip hand upstream. Gross margin >80% is the receipt.

4. The R&D paradox. Keyence spends only ~2.3% of revenue on R&D — versus Cognex ~14%, FANUC ~6.8%, Omron ~5.8%, Rockwell ~5.7%. It out-innovates on a fraction of the budget because the salesforce does the discovery — R&D is aimed, not speculative. Rivals spend 3–6x more and grow slower.

The scoreboard: FY2012–2023 revenue 15% CAGR vs. Cognex 10.9%, SMC 7.6%, Yaskawa 5.5%, FANUC 4.3%, Omron 3.2%, Rockwell 2.4%. Keyence has out-compounded every automation peer, overseas revenue growing ~22% CAGR — all organic.

Where the moat is thinnest: in commodity sensor/vision categories, emerging Chinese vendors are undercutting on price by 30–50%. Keyence's defense is to stay ahead on the solution layer, not the component — but this is the edge bulls should watch.

Lens 4 · Segments

Keyence reports as a single statutory segment and does not publish product-line P&L — so any product-family split is n/a at the revenue-and-margin level. segments.csv on the shelf is empty (headers only). What is knowable:

By product family (qualitative, no P&L split disclosed): five groups — (1) Sensors (the core), (2) Measurement systems & microscopes, (3) Machine vision (described as a global 3D-vision leader), (4) Marking & printing (laser markers, traceability/code-reading), (5) Process control (PLCs, servos, HMIs). Machine vision and measurement are the higher-growth, higher-margin end; sensors are the volume base.

By geography (the split that is disclosed):

• Overseas ≈ 60% of revenue, all organic, up from ~48% a few years ago — the growth engine.
• FY2024 mix cited as Japan ~36%, USA ~18%, China ~15%, rest-of-world the remainder.
• China exposure is the swing factor. Direct China ~15%, but broader "Greater China + China-linked demand" is cited as high as ~30% of revenue — the single most important cyclical variable (Lens 12/13).

Regional trend (direction & cause): FY2024 quarterly YoY — Japan +8.5%, Americas +12.6%, Asia +17.7% (China recovering), but Europe −6.5%. FY2026 growth (+10.4%) was led by North America and Asia, specifically automotive and semiconductor capex. Read: the Americas + Asia semiconductor/automation build is the accelerant; Europe is the drag; China is the wildcard that can swing the whole print.

---

Phase B — Measure performance

Lens 5 · Earnings Result (FY2026, year ended March 2026)

The latest full-year print was another record, with one landmark strategic addition.

• Net sales ¥1.17T, +10.4% YoY — first time comfortably clear of the ¥1T "sound barrier," reaccelerating after a soft FY2024.
• Operating income ¥595.7B, +8.4%; operating margin 51.0% — note the margin ticked down from ~51.9% (FY2025) as opex (salesforce expansion, overseas build-out) grew slightly faster than sales. Not alarming, but the +8.4% OP vs. +10.4% sales gap is the one line a bull should keep an eye on.
• Net income ¥445.1B, +11.7% — 5th straight record; net margin ~38%.
• ROE 13.5% — artificially depressed by the cash mountain (see Lens 9); operating ROIC ex-cash is an order of magnitude higher.
• Q4 was the fireworks: operating profit ¥179.4B vs. ¥163.8B consensus, and the stock jumped 16% to its daily limit on the beat.

Balance sheet (fortress): total assets ¥3.67T, equity ratio 94.6% — i.e. almost no debt. Marketable + investment securities ¥2.38T (gov't bonds ¥600B, corporate bonds ¥864B, CDs ¥891B, plus deposits/equities) on top of ~¥451B cash equivalents — so ~¥2.8–3.0T of the ¥3.67T asset base is liquid financial assets. Working capital is deliberately loose: ~163 days inventory (funds the delivery promise), ~108 days receivables (generous terms to small customers). No inventory/receivable quality flags — these are strategy, not stress.

Guidance/outlook: the ¥350→¥550 dividend hike (payout to 30%) was signaled to be maintained into next year, and management moved to amend the charter to enable buybacks (Lens 9) — the tone shifted from "hoard" to "return." Forward company guidance figures: n/a in parseable form.

Vs. its own history: the standout unusual item is not in the P&L — it's the capital-allocation pivot. For a company whose entire bear case was "dead money on the balance sheet," FY2026 is the year that thesis started to break in the bulls' favor.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the shelf (transcripts=0), and Keyence is famously low-touch with investors — sparse guidance, minimal management access, no IR theatre. Sentiment must be read off actions and results commentary rather than call tone.

The trend across the last several prints (FY2024 → FY2026):

• FY2024: defensive — revenue declined ~6% in USD terms, Europe weak (−6.5%), China soft; management stayed quiet and let the model absorb the down-cycle. Message: "we compound through cycles."
• FY2025: reacceleration — back above ¥1.06T, +9.5%, led by North America and Asia semiconductor/automotive.
• FY2026: confidence — record profit #5, and the language of the announcement changed. The dividend near-doubling and the buyback-charter move are, for this management, a loud statement. The thing they stopped implying is "cash stays idle indefinitely."

The durable "recurring phrases" are structural: added-value, world-first products, sales-network strength, overseas expansion. The new note is shareholder return — a genuine tonal shift for a company that spent decades saying nothing about capital.

Lens 7 · Comps

Machine-vision / factory-automation peer set. Multiples are `` with source/date or n/a. No multiple is fabricated.

Dividend yield: Keyence ~0.7% at the ¥550 dividend on a ~¥63–80k share price — negligible; this is a growth-compounder, not an income name. 5-yr avg ROE: mid-teens (13–15%), cash-suppressed.

Read: Keyence and Cognex trade at statistically identical forward multiples (~42–43x), and FANUC isn't far behind (~39x) — the whole quality-automation complex is priced for perfection. But Keyence earns a ~50% operating margin vs. Cognex's teens and FANUC's ~20s, grows faster and more consistently, and carries a net-cash fortress. On quality-adjusted terms Keyence is the cheapest expensive stock in the group — you pay ~43x for a business that genuinely deserves a premium. Historical P/E band: 10-yr avg ~30–35x, low ~20x (2016), high ~68x (2021) — so ~43x sits above mid-cycle but well below the 2021 bubble peak.

Lens 8 · Stock-Price Catalysts (moves >5%, last ~5 years)

The pattern is unusually clean: Keyence trades on the global automation/semiconductor capex cycle and on earnings surprises — not on company-specific drama.

• 2021 (peak, ~68x P/E): rode the post-COVID automation + semiconductor super-cycle to an all-time high; briefly made founder Takizaki Japan's richest man.
• 2022–2023 (de-rate): global rate shock + automation down-cycle compressed the multiple hard from the 2021 peak; the business held up far better than the stock (revenue kept growing) — a valuation event, not a fundamental one.
• FY2024 (soft patch): USD revenue −6%, Europe −6.5%, China weak → stock pressured on the automation slowdown.
• 27 Apr 2026 (+16%, daily limit): Q4 OP ¥179.4B crushed ¥163.8B consensus on strong overseas sales — the single biggest one-day move, and it paired the beat with the dividend hike + buyback-charter news. The market reacted violently upward because two things it wanted — a beat and capital return — arrived together.
• 52-week range (ADR KYCCF) ~$303–$553 → an ~80% high-to-low swing, i.e. the name is volatile despite the fortress balance sheet, because it's a high-multiple cyclical.

What the market actually reacts to: (1) earnings surprises vs. consensus (semiconductor/auto capex is the driver), (2) China/Asia demand signals, and — newly — (3) capital-return news. The April 2026 reaction proves the market has been waiting for Keyence to address the cash; every step toward returning it is now a catalyst.

---

Phase C — Judge people & books

Lens 9 · Management

• Founder: Takemitsu Takizaki (b. 1945), founded Keyence 1974, stepped back to Honorary Chairman in 2015. Net worth ~$16–19B — was briefly Japan's richest person (2021). Still controls ~18% directly + through holding company TT K.K., with a related asset-management vehicle holding another ~17%. Founder DNA is intact even without founder in the chair.
• CEO/President: transitioned to Yu Nakata (President & Representative Director, ~2025) from Akinori Yamamoto (President 2010–~2025). (Note: source variation on exact current title/name — treat as ``, medium confidence.) Keyence's model is deliberately CEO-light: the system (Needs Cards, salesforce discipline, fabless economics) runs the company, not a charismatic operator. Value Punks called the top job a "revolving door" (3+ CEOs since 2000) — and it hasn't mattered, which is itself the point.

(1) Track record: the machine speaks — 15% revenue CAGR, ~50% margins, 5 straight record profits, all-organic overseas expansion. Best-in-class execution, sustained across cycles and CEOs.

(2) Tenure & skin in the game: founder family ~35% combined economic interest via direct + vehicles — enormous alignment. Insider-transactions file n/a — not on shelf.

(3) Capital-allocation history — the crux, and it's changing:

• Historically the one blemish. Keyence hoarded. Dividend payout was 6% of net income in 2018, crawling to ~20%, described as "immaterial". It built a ~¥2.4T securities / ~¥2.8–3T total liquid pile earning near-nothing while the operating business earned ~100% ROIC — a textbook value-destroying idle-cash drag that suppressed group ROE to the mid-teens.
• FY2026 = the inflection. Dividend near-doubled ¥350→¥550 (payout to 30%), signaled to hold; and management moved to amend the charter to enable buybacks. Under TSE's "cost-of-capital-conscious management" reform (the ¥/P-B campaign pushing Japanese firms to return capital), Keyence is finally addressing its single structural weakness. This is the most important development in the whole dossier.

(4) Red flags: the 2016 gift-tax affair — founder's elder son failed to report ~¥150B in gift tax on shares of the family asset-management firm (which holds ~17% of Keyence), settling ~¥30B in back taxes. It's a family-succession/tax-structuring matter, not corporate fraud — but it flags aggressive family-wealth engineering and the opacity of the ownership vehicles. Separately, the salesforce culture draws heavy criticism (relentless cold-calling, extreme quotas, "customers hate the daily calls") — a reputational/retention risk, not an accounting one.

(5) Archetype: founder-built, now system-run — the rare case where the founder's genius was encoded into a process durable enough to outlast him. That's the bull's core comfort and the reason CEO churn doesn't scare the stock.

Lens 10 · Forensic Red Flags

Forensic-analyst lens. Every figure /; no SEC filings exist to cross-check, which is itself a limitation — treat conclusions as medium-confidence.

Income statement: margins are so high they invite skepticism, but ~50% operating / >80% gross has held for years across independent sources and cycles — consistency argues against a one-off distortion. Revenue recognition is point-of-sale hardware (clean, low judgment). No non-GAAP/SBC games of the US-tech kind — this is Japanese-GAAP hardware; stock-based comp is not a material margin flatterer here (a genuine positive vs. the SBC-inflated US comps). The one thing to watch: OP grew +8.4% vs. sales +10.4% in FY2026 — mild opex deleverage, worth monitoring but immaterial.

Balance sheet: the flag is not fraud — it's capital inefficiency. ~¥2.4T in securities + ~¥451B cash (94.6% equity ratio) is a fortress that was, until FY2026, a value trap — a mountain of low-return financial assets depressing ROE. Receivables (~108 days) and inventory (~163 days) run high by deliberate strategy (small-customer terms + the delivery promise), not deterioration — but a forensic analyst notes that generous receivables to small customers can mask channel-stuffing risk in a downturn; no evidence of it, but it's the place to look if growth ever stalls. Goodwill/intangibles are negligible (organic growth, ~no M&A) — a clean balance sheet with no acquisition-accounting risk.

Cash flow: FCF conversion ~80–90% of net income — cash earnings track book earnings well; no divergence between earnings and cash (the classic red flag) is absent. Capex is trivial (fabless), so FCF ≈ operating cash flow ≈ net income — high quality of earnings.

Segment/disclosure opacity: Keyence reports one segment and does not name its contract manufacturers or break out product-line economics. This is legal under J-GAAP and consistent with its secretive culture, but it reduces external verifiability — you cannot independently check where the margin comes from by product. A forensic minus for transparency, not for integrity.

Regulatory findings (required sub-section):

• SEC (EDGAR LR/AAER): none possible — Keyence has no CIK and is not an SEC filer. regulatory/regulatory-findings.md (fetched 2026-07-06) confirms total_sec_findings: 0, noting "Keyence has no CIK … no EDGAR enforcement search is possible".
• Non-SEC / web ("Keyence" (FTC OR DOJ OR FDA OR consent decree OR fine OR penalty) enforcement): no material antitrust, product-safety, or enforcement actions surfaced. The only material legal/tax matter is the 2016 family gift-tax settlement (~¥150B assessed, ~¥30B paid) — a shareholder/family tax matter, not a corporate enforcement action against Keyence Corp.
• Item 3 Legal Proceedings: n/a — no 10-K exists (non-US filer).
• Verdict: No material corporate regulatory or fraud findings — verified via the (empty) SEC EDGAR EFTS pull and web search as of 2026-07-06. The standing flags are governance/disclosure opacity and family-wealth structuring, not accounting fraud.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

Built bottom-up from FY2026 actuals (net income ¥445.1B, ~243M shares, EPS ≈ ¥1,830 ). All output lines `` with arithmetic; no consensus EPS was cleanly sourceable, so this is a model, not a print.

Assumptions (labeled):

• Machine-vision/automation TAM +8.3% CAGR to 2030; Keyence historically grows ~1.5–2x the market via share gains.
• Margins ~stable at ~50–51% (slight opex deleverage offset by mix toward vision/measurement).
• Dilution ~0; buybacks now a tailwind to per-share figures if the charter amendment passes.

. ~3-year base EPS CAGR ~8–9%; at ~43x that leaves little valuation cushion — the stock needs the bull path (or multiple support from capital return) to make double-digit forward returns.

Brier forecast: skipped create step (unattended --watchlist rule — only log when genuinely committed to the base case). Would-be forecast for the record: "6861.T FY27 (Mar-2027) net income ≥ ¥480B, p≈0.60, resolves 2027-05-31" — logged here as a note, not written to forecast.ts.

Lens 12 · Bull vs Bear

Bull case. You are buying the single best hardware business model ever assembled, and its one flaw is finally being fixed. The consultative-salesforce + fabless-economics moat has out-compounded every automation peer for 40 years at ~50% margins and ~100% operating ROIC, and it survives CEO turnover because it's a system, not a person. Secular tailwinds — reshoring, factory automation, semiconductor capex, labor scarcity, AI-based inspection — all pull Keyence's way, and it grows ~2x the market via share gains. The FY2026 catalyst is real and repricing-worthy: the dividend near-doubled and buybacks are coming, so the ~¥2.8T of dead cash that suppressed ROE to the mid-teens is about to start working — a mechanical boost to ROE, EPS, and the multiple, exactly what TSE governance reform is engineering across Japan. Earnings-surprise history is a positive skew (8+ consecutive beats, +16% on the last one). This is a compounder you hold for a decade.

Bear case (permanent-impairment risks).

1. China (~30% of demand) structurally decelerates. A prolonged Chinese industrial slump plus domestic Chinese vision/sensor champions undercutting by 30–50% in commodity tiers could permanently reset Keyence's growth and its pricing power in its biggest growth market. This is the crack.
2. Valuation compression. ~43x forward with ~8–9% base EPS growth = priced for perfection. The 2022–23 de-rate showed the stock can lose a third of its value on no fundamental deterioration — a multiple event. If growth merely normalizes, the multiple does the damage.
3. The moat's commodity edge erodes. If AI-based vision becomes "good enough" as a cheap software/commodity layer, Keyence's premium-hardware ROI pitch weakens at the low end.

Pre-mortem (18 months out, thesis broke — what happened?): China demand rolled over hard, a global automation capex freeze hit orders (peers see 30–40% order drops in a quarter in true down-cycles), Keyence printed a flat-to-down year for the first time in a while, and the ~43x multiple compressed toward its ~20x floor — a 40–50% drawdown with the business still intact. The killer isn't the model; it's cyclicality meeting a rich multiple.

Are multiples too high? Above mid-cycle (~43x vs. ~30–35x 10-yr avg), but defensible given the margin/ROIC quality and the capital-return catalyst. Not a bubble (2021 was 68x). The risk is timing, not overvaluation-to-the-point-of-absurdity.

Contrarian view (what the market refuses to see): the consensus fixates on "expensive + China risk." What's under-appreciated is the capital-allocation regime change: a company that returned 6% of profit in 2018 and 20% recently just went to 30% and opened the door to buybacks. If Keyence follows the TSE-reform playbook to its conclusion, the ¥2.8T cash is a loaded spring — years of buybacks that mechanically lift ROE from the mid-teens toward the 20s and re-rate the multiple. The market is pricing the cash as dead; it's about to come alive.

Lens 13 · Devil's Advocate (short-seller)

Skeptical short-seller dismantling the bull case.

• What structurally breaks the money machine? Keyence's margin is a function of pricing power in a premium niche. The most dangerous scenario isn't a cyclical dip — it's commoditization from below: Chinese vision/sensor vendors (backed by state industrial policy) climbing the value chain at 30–50% lower prices, turning Keyence's "world-first feature" premium into a shrinking island. In China specifically — its single biggest growth market — "buy domestic" policy is a structural, not cyclical, headwind.
• Revenue concentration: not customer-concentrated, but geography-concentrated on the cycle — ~30% China-linked, heavy semiconductor/auto capex exposure. Both are among the most volatile demand pools in the global economy. A synchronized China + semicap downturn hits the growth and the multiple at once.
• Why the moat is weaker than bulls think: the salesforce moat is a culture — and cultures are fragile to scale and geography. The relentless-cold-call, extreme-quota model that works in Japan draws open customer hostility abroad ("customers hate the daily calls" ); replicating 3,000 elite engineer-consultants across 110 countries as the company scales is not guaranteed, and salesforce burnout/turnover is a real degradation vector.
• Most dangerous competitor bulls underestimate: not Cognex (same premium game, similar multiple) — it's the Chinese long tail plus AI-vision-as-software players who could make "good-enough" inspection cheap and undercut the hardware-ROI pitch at the volume base.
• Worst capital-allocation history: a decade-plus of hoarding ¥2T+ at near-zero return while earning ~100% operating ROIC — a colossal, quantifiable value-destruction that only now is being addressed, and only under external (TSE) pressure. Plus the 2016 gift-tax affair and opaque family holding vehicles — aggressive family-wealth structuring and disclosure opacity (single segment, unnamed CMs). Governance-minded investors should not wave this away.
• Assumptions that must hold for today's price: sustained ~8–10% growth, ~50% margins intact despite Chinese price pressure, China recovering, and the buyback promise actually executing. That's a lot of "and."
• Valuation if growth disappoints 20–30%: at ~43x, a growth scare that resets the multiple toward the ~20x historical floor is a ~40–50% drawdown even with earnings only modestly lower — the 2022–23 episode is the template.
• Single scenario that permanently impairs: Chinese domestic champions + AI-commodity vision permanently cap Keyence out of its biggest growth market and compress its premium — turning a 15%-CAGR compounder into a low-single-digit, ex-growth industrial that de-rates from ~43x to ~15–20x. Plausibility: moderate — the low-end erosion is real and observable; the complete impairment is not the base case but is the tail worth respecting.

Lens 14 · Management Questions (ordered by information value)

1. The charter amendment enables buybacks — what is the actual capital-return policy and target payout/net-cash ratio? Will you commit to a multi-year buyback that draws the ¥2.4T securities pile down, or is this optionality you may never use? (This answer most changes the thesis — it's the entire capital-allocation crux.)
2. In China (~30% of demand), how much of recent softness is cyclical vs. structural "buy-domestic" policy, and how are you defending share against Chinese vendors pricing 30–50% below you?
3. Where are AI-based/software vision approaches most threatening to your premium-hardware ROI pitch, and how does your software layer defend the value base — not just the frontier?
4. Operating profit grew slower than sales in FY2026 — is ~50% the durable margin floor, or should we model gradual deleverage as you scale the overseas salesforce?
5. Can the consultative-salesforce culture be replicated at full fidelity across 110 countries as you scale, and what is engineer-consultant turnover outside Japan?
6. What is the right net-cash level for this business? Why hold ¥2.8T of low-return financial assets against a ~100% operating-ROIC core?
7. How do you sustain ~70% "world-first" new-product hit rate on just ~2.3% of sales in R&D as the SKU base and TAM expand?
8. Which product family (vision, measurement, microscopy, marking, sensors) has the best 5-year growth/margin outlook, and why won't you disclose product-line economics?
9. What's the succession/development plan for the engineer-consultant salesforce given documented burnout and customer-relationship friction?
10. How exposed is the model to a synchronized semiconductor + automotive capex down-cycle, and what did FY2024 teach you about the trough?
11. Reshoring/friend-shoring — quantify the incremental automation demand you expect in the US/India/SE Asia over five years.
12. How do you think about M&A now that you're returning capital — is inorganic growth permanently off the table, and why?
13. What governance changes (beyond buybacks) are you making under the TSE cost-of-capital initiative — board independence, disclosure, the family holding vehicles?
14. Contract-manufacturer concentration and geographic footprint — how resilient is the fabless supply chain to a chip/optics shortage or a Taiwan/China disruption?
15. If you had to name the one thing most likely to end the 15% compounding, what would it be?

---